Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays.

BACKGROUND Bladder cancer is characterized by genomic instability. In this study, we investigated whether genome-wide screening using single-nucleotide polymorphism (SNP) arrays could detect allelic imbalance (loss or gain of at least one allele) in bladder cancers. METHODS For microarray analysis, DNA was isolated from microdissected bladder tumors and leukocytes from 11 patients. The stage T1 tumor (connective tissue invasive) and the subsequent stage T2-4 tumor (muscle invasive) were available from eight of these patients, and only the first muscle-invasive stage T2-4 tumor was available from three of the 11 patients. The microarray contained 1494 biallelic polymorphic sequences. For microsatellite analyses, DNA was isolated from tumors and leukocytes of nine patients with primary T2-4 tumors and 13 patients with Ta (noninvasive) tumors. All statistical tests were two-sided. RESULTS We assigned a genotype to 1204 loci, 343 of which were heterozygous. Allelic imbalance was detected in known areas of imbalance on chromosomes 6, 8, 9, 11, and 17, and a new area of imbalance was detected on the p arm of chromosome 6. Microsatellite analysis of nine other T2-4 tumors and 13 Ta tumors showed that allelic imbalance was more frequent in T2-4 tumors than in Ta tumors (P<.001). We detected 8.5 allelic imbalances (median) in 348 informative loci in T1 tumors and 28 allelic imbalances (median) in 329 informative loci in T2-4 tumors. When pairs of T1 and T2-4 tumors were analyzed from eight patients, 68% of imbalances detected in T1 tumors (146 imbalances) occurred in the subsequent T2-4 tumors (99 imbalances). Homozygous TP53 mutations were more often associated (P =.005) with high allelic imbalance than with low allelic imbalance. CONCLUSION SNP arrays are feasible for high-throughput, genome-wide scanning for allelic imbalances in bladder cancer.

[1]  S. Brosman,et al.  Bladder tumors. Treated natural history. , 1986, Progress in clinical and biological research.

[2]  Pui-Yan Kwok,et al.  Single-nucleotide polymorphisms in the public domain: how useful are they? , 2001, Nature Genetics.

[3]  Wanggang,et al.  Genetic aberration in primary hepatocellular carcinoma：correlation between p53 gene mutation and loss—of—heterozygosity on chromosome 16q21—q23 and 9p21—p23 , 2000 .

[4]  S. Zienolddiny,et al.  Loss of heterozygosity is related to p53 mutations and smoking in lung cancer , 2001, British Journal of Cancer.

[5]  H. Moch,et al.  Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. , 1998, The American journal of pathology.

[6]  H. von der Maase,et al.  Allelic deletions of cell growth regulators during progression of bladder cancer. , 2000, Cancer research.

[7]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[8]  W. Schulz,et al.  Delineation of the 6 p 22 Amplification Unit in Urinary Bladder Carcinoma Cell Lines 1 , 2000 .

[9]  G. Aguiari,et al.  LOH of chromosome 6q compared with LOH of 17q and 18q in ovarian cancers: relationship to p53 expression and clinicopathological findings. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[10]  D J Lockhart,et al.  Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. , 2000, Genome research.

[11]  W. Schulz,et al.  Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. , 2000, Cancer research.

[12]  Eric S. Lander,et al.  Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays , 2000, Nature Biotechnology.

[13]  T. Ørntoft,et al.  Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity. , 2001, Carcinogenesis.

[14]  S. Devries,et al.  Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.

[15]  H. Moch,et al.  Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. , 1997, Cancer research.

[16]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[17]  H. Huland,et al.  Relevance of p53 Gene Alterations for Tumor Recurrence in Patients with Superficial Transitional Cell Carcinoma of the Bladder , 2001, European Urology.

[18]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[19]  U. M. Moll,et al.  p53--an acrobat in tumorigenesis. , 1998, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[20]  Gang Wang,et al.  Genetic aberration in primary hepatocellular carcinoma: correlation between p53 gene mutation and loss-of-hetero- zygosity on chromosome 16q21-q23 and 9p21-p23 , 2000, Cell Research.